SCHEMBL30196003

SCHEMBL30196003

CN(C)C(=O)c1ccc(-c2ccc3[nH]cc(NC(=O)Nc4ccc(C(F)(F)F)cc4)c3c2)c(F)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ STING1 Q86WV6 5/20 0.53
▸ IGF1R P08069 4/20 0.42
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ KDR P35968 4/20 0.41
▸ FLT3 P36888 3/20 0.41
▸ KIT P10721 2/20 0.41
▸ PIM1 P11309 1/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ RIPK1 Q13546 3/20 0.39
▸ PDGFRB P09619 2/20 0.39
▸ NTRK1 P04629 1/20 0.39
▸ RET P07949 1/20 0.39
▸ LTK P29376 1/20 0.39
▸ CDK8 P49336 1/20 0.39
▸ NTRK3 Q16288 1/20 0.39
▸ MAPK14 Q16539 1/20 0.39
▸ NTRK2 Q16620 1/20 0.39
▸ AURKB Q96GD4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23207770 1.00 STING1 (0.53) STING1IGF1RNPC1RAB9AKDR
SCHEMBL23208223 0.89 STING1 (0.59) STING1NPC1RAB9AMEN1KMT2A
SCHEMBL23207919 0.86 STING1 (0.60) STING1IGF1RKDRFLT3KIT
SCHEMBL23207917 0.80 STING1 (0.65) STING1KDRFLT3KITMEN1
SCHEMBL30195938 0.80 STING1 (0.65) STING1KDRFLT3KITMEN1
SCHEMBL23208192 0.79 STING1 (0.67) STING1IGF1RRAB9AKDRFLT3
SCHEMBL23208067 0.78 STING1 (0.65) STING1RAB9AMEN1KMT2A
SCHEMBL30196046 0.78 STING1 (0.65) STING1RAB9AMEN1KMT2A
SCHEMBL23208193 0.78 STING1 (0.65) STING1IGF1RRAB9AMEN1KMT2A
SCHEMBL22803837 0.77 STING1 (0.77) STING1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002320-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-01-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002320-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 STING1 1/4885IGF1R 2527/4885NPC1 861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback